Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

terazosin (Rx)Brand and Other Names:Hytrin

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule

  • 1mg
  • 2mg
  • 5mg
  • 10mg
more...

Benign Prostate Hyperplasia

Initial: 1 mg PO qHS

May gradually increase to 5 mg PO qHS; up to 20 mg/day beneficial for some

Dosing considerations

  • Give first dose and subsequent increases at bedtime to avoid syncope
  • May take with food

Hypertension

Initial: 1 mg PO qHS

Maintenance: 1-5 mg/day or q12hr; may increase to ≤20 mg/day

Dosing considerations

  • Give first dose and subsequent increases at bedtime to avoid syncope
  • May take with food

Dosing Modifications

Hepatic impairment: Use with caution

Dosage Forms & Strengths

capsule

  • 1mg
  • 2mg
  • 5mg
  • 10mg
more...

Hypertension (Off-label)

1 mg/day PO; increase dose gradually as necessary; up to maximum of 20 mg/day

Hypertension

Initial: 0.5 mg PO qHS and titrate to response

Dosing considerations

Avoid use for hypertension; high risk of orthostatic hypotension (Beers criteria)

May cause significant orthostatic hypotension and syncope

Lower initial doses than those used for nongeriatric adults, as well as gradual adjustments, are recommended for hypertension

Give first dose and subsequent increases at bedtime to avoid syncope

Adverse effects such as dry mouth and urinary complications can be bothersome in the elderly

May take with food

Next

Interactions

Interaction Checker

terazosin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Dizziness (10-20%)

            Asthenia (2-13%)

            1-10%

            Hypotension (3-7%)

            Rhinitis/nasal congestion (2-6%)

            Lightheadedness (3-5%)

            Somnolence (3-5%)

            Palpitation (4%)

            Nausea (2-4%)

            Edema (3%)

            Sinusitis (3%)

            Dyspnea (2-3%)

            Fatigue (2.5%)

            Headache (2.5%)

            Back pain (2.4%)

            Flulike syndrome (2.4%)

            Tachycardia (2%)

            Amblyopia (1-2%)

            Blurred vision (1-2%)

            Impotence (1-2%)

            Syncope (1%)

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to terazosin, other quinazolines

            Cautions

            Prostate carcinoma

            Liver disease

            May cause first-dose syncope/sudden LOC and orthostatic hypotension; minimize effect by using small first dose at bedtime; increase dose slowly

            Concomitant use of other antihypertensives (additive hypotensive effects)

            Concomitant administration with PDE-5 inhibitor (eg, sildenafil) can result in additive blood pressure-lowering effects and symptomatic hypotension; initiate PDE-5 inhibitor therapy at lowest dose

            Risk of priapism (rare but needs medical attention)

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Not known if excreted into breast milk; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Blocks postsynaptic alpha-1 receptor; alpha blockade causes arterial and venous dilation

            Selective agents cause less tachycardia than do nonselective agents

            Absorption

            Bioavailability: 90%

            Onset (hypertension): 3 hr

            Onset (benign prostate hyperplasia): 2 weeks

            Duration: 24 hr

            Peak response (benign prostate hyperplasia): 4-6 weeks

            Peak plasma time: 1 hr

            Distribution

            Protein bound: 90-94%

            Vd: 25-30 L

            Metabolism

            Metabolized extensively via hydrolysis, O-demethylation, and N-dealkylation in liver

            Metabolites: 6- and 7-O-demethyl terazosin, piperazine derivative, diamine metabolite

            Elimination

            Half-life: 9-12 hr

            Renal clearance: 9-12.5 mL/min

            Excretion: Feces (55-60%); urine (40%)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.